This study involves the prospective collection of samples from well-characterized Parkinson’s patients combined with Arrayit’s new H25K microarray technology.
The first experiments have enabled rapid and efficient sample preparation of specimens from Parkinson’s disease patients, an important step in the discovery of molecular markers for Parkinson’s disease, the company said.
Mark Schena, president of Arrayit, said: “This collaboration provides an important first step towards unraveling the mysteries of Parkinson’s disease. We look forward to working with The Parkinson’s Institute to decipher the molecular basis of the disease.”